Health problems in the country are not going away. Other illnesses are also plaguing Corona’s epidemic. Mucormycosis has created a great deal of fear. According to reports, the treatment of this problem is very expensive. And not only that, the injections used in the treatment of this are also very difficult to get.
News of relief has come from Hyderabad in such a time of wailing. A research team from IIT Hyderabad has come up with an effective solution to treat black fungus. Which is said to be given to the patient by mouth. This medicine is a tablet.
How much does it cost?
The IIT said in a publication on Saturday that 60 mg of the drug is patient-friendly and gradually reduces nephrotoxicity (side effects of drugs and chemicals on the kidneys) in the body. This is a tablet taken orally. Which is only 60 mg. And it costs only 200 rupees.
The researcher had been working on this research for two years, now he has full confidence in his research. He believes that this can be given for mass production. One of the special things about this solution is that it is very affordable.
Achievement found after two years of research
Let us know who has worked on this research. Professor Saptarishi Majumdar, Dr. Chandra Shekhar Sharma and their PhD scholars Mrinalini Gedhane and Anandita Laha have been working on this solution for the last two years at IIT Hyderabad. Let me tell you, this is not a coronary disease. The disease has been seen for many years.
“After two years of study, researchers are confident that this discovery could be passed on to the right pharma partner for mass production.” This was stated by the organization regarding this discovery.
The organization also said that “Kala Azar is currently being used in the country for the treatment of black fungus and other fungi. And in view of its availability and affordability, immediate testing of this drug should be allowed. ”
Research car doctor Sharma said the technology has been kept free of intellectual property rights so that it can be made widely available to the people at affordable and accessible rates.